Nintedanib and pirfenidone arethe only FDA-approved drugs to treatpulmonary fibrosis.50 Additionally, nintedanibshowed its antifibrotic effect in a mouse model of systemic sclerosis,34 and pirfenidone showed its therapeutic use inscleroderma patients.51 Moreover, nintedanibis known to inhibit TGFβ1-induced myofibroblast proliferationand gene expression,32 and consequently,we may expect that both drugs will affect particularly the myofibroblastcultures in cell proliferation and expression levels of all studiedgenes, as well as the production of αSMA and collagen. Here, TGFB1 is linked to systemic sclerosis.